Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC
Status:
Recruiting
Trial end date:
2028-09-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in
participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or
high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.